Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

Back to Healio The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two or three is ending early due to robust positive evidence ...

Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION study RAHWAY, N.J., January 30 ...

Merck gained Winrevair in its $11.5 billion acquisition of Acceleron in 2021 and got it across the FDA finish line in March of 2024 based on results from the phase 3 STELLAR trial.

Merck & Co. has ended another late-stage study of its Winrevair treatment for pulmonary arterial hypertension, or PAH, early due to strong evidence of the drug's benefit. Merck on Thursday said ...

MSD has put a stop to its Phase III HYPERION study investigating its pulmonary arterial hypertension (PAH) treatment Winrevair after the therapy provided positive results from another Phase III trial.

This decision suggests that Winrevair has shown significant benefits for patients with pulmonary arterial hypertension, which was initially observed in the STELLAR trial. Graybosch believes that ...

Merck, known as MSD outside of the United States and Canada, announced the phase 3 HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) ...

Researchers have now uncovered the 3D structure of the RNA enzyme SAMURI. Their study provides insights into the development of ribozymes and the evolution of catalytically active RNA. Researchers ...

Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION study RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...